Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs RIGL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 10–0 Matrix Metrics)

RIGL Overall Winner 6-Pillar Tally: RGNX 2 – 4 RIGL Matrix Metrics: RGNX 0 – 10 RIGL

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas RIGL carries 59.9/100 (HOLD) at $43.73 (9.3x Forward P/E, 26.3% operating margin).

  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs RIGL
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.73
-1.64% 1D
Market Cap $860.3M
TTM Revenue $288M
Forward P/E 9.3x
Beta / 30D Vol 1.05β · 74% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.6 · SMA20: $47.42 · SMA50: $47.34

6-Pillar Scorecard Institutional Category Breakdown (RGNX 2 – 4 RIGL)

Columns: Metric · RGNX · RIGL
1. Valuation Multiples RIGL
Forward P/E N/M 9.3x
Trailing P/E N/M 2.8x
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 2.9x
2. Growth & Scale RIGL
Revenue Growth (YoY) -69.2% +16.5%
Earnings Growth (YoY) +0.0% -55.5%
TTM Revenue (USD) $154M $288M
Market Cap $500.9M $860.3M
3. Profitability & Quality RIGL
Gross Margin -64.5% 70.7%
Operating Margin -120.4% 26.3%
Net Profit Margin -113.9% 106.6%
Return on Equity (ROE) -113.2% 109.2%
4. Balance Sheet & Cash Flow RIGL
Cash Generation (TTM) -$155M $19M
Cash Flow Margin -100.6% 6.7%
Net Cash / Leverage $29M Net Cash $39M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 349.6% (52nd %ile) 61.2% (4th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) 44.4% of Rev ($128M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (0) vs RIGL (10)
Institutional Metric RGNX RIGL Criterion Row Edge
Market Capitalization
Scale
$500.9M $860.3M Larger Scale RIGL
Trailing P/E Ratio
Valuation
N/M 2.8x Lower Multiple RIGL
Forward P/E Ratio
Valuation
N/M 9.3x Lower Multiple RIGL
Revenue Growth (YoY)
Growth
-69.2% +16.5% Higher Growth RIGL
Operating Margin (TTM)
Profitability
-120.4% 26.3% Higher Margin RIGL
Net Profit Margin
Profitability
-113.9% 106.6% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
-113.2% 109.2% Higher ROE RIGL
52-Week Range Position
Momentum
19% ($5–$16) 68% ($25–$53) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 1.05β · 74% Vol Lower Realized Risk RIGL
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 59.9 / 100 (HOLD) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$154M $288M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% 70.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 2.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) $19M ($39M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +12.74 pp
RGNX: +7.87% · RIGL: -4.87%
3M Horizon RIGL +32.77 pp
RGNX: -32.52% · RIGL: +0.25%
6M Horizon RIGL +20.64 pp
RGNX: +32.21% · RIGL: +52.85%
1Y Horizon RIGL +45.47 pp
RGNX: -35.82% · RIGL: +9.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue RIGL Revenue RGNX Op. Margin RIGL Op. Margin Margin Leader
FY2018 $220M $40M 40.3% -163.3% RGNX
FY2019 $40M $60M -422.9% -116.5% RIGL
FY2020 $150M $110M -77.1% -26.7% RIGL
FY2021 $470M $150M 34.0% -8.4% RGNX
FY2022 $110M $120M -233.2% -46.2% RIGL
FY2023 $90M $120M -297.1% -17.5% RIGL
FY2024 $80M $180M -280.0% 13.5% RIGL
FY2025 $170M $290M -94.6% 42.6% RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RIGL CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 61.2%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $860.3M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs RIGL Key Questions & Quantitative Answers

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas RIGL carries 59.9/100 (HOLD) at $43.73 (9.3x Forward P/E, 26.3% operating margin). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RIGL leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with RIGL at +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while RIGL shifted +625.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus 44.4% of Rev ($128M) (0 disclosures) for RIGL.

RIGL screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus RIGL (109.2% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.05β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.